Min-Han Tan, CEO and Medical Director at Lucence, shared a post by Lucence on LinkedIn:
“A common clinical challenge is the cancer patient presenting with new-onset headache from brain metastasis that may be missed by radiology and cytology.
How can amplicon-based NGS overcome the low ctDNA yields in CSF, to help improve detection, and what are the practical considerations around accuracy and sampling?
Honored to participate in an upcoming webinar with GILBERTO de lima LOPES Junior focusing on the role of CSF liquid biopsy for cancer patients worldwide.”
Quoting Lucence’s post:
“You’re Invited: Educational Webinar / CSF-Based Molecular Profiling for CNS Malignancies
Join us for a clinical conversation featuring Dr. GILBERTO de lima LOPES Junior and Dr. Min-Han Tan who will be discussing the role of LiquidHALLMARK® CSF in molecular profiling for primary and secondary central nervous system (CNS) malignancies.
Date: Wednesday, July 22, 2026
Time: 8:00 PM ET
This session will explore how CSF-based liquid biopsy can support precision oncology by providing actionable molecular insights for patients with CNS tumors.
Whether you’re an oncologist, neuro-oncologist, pathologist, or other healthcare professional involved in the care of patients with CNS malignancies, we invite you to join us for this informative discussion.
Register today by scanning the QR code on the event flyer, or by clicking this link.
We look forward to seeing you there!”
Other articles about Min-Han Tan on OncoDaily.